SCHEMBL22793158

SCHEMBL22793158

CC(C)(C)c1c2ccccc2cn1C(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.32
▸ CYP2A6 P11509 2/20 0.32
▸ TSHR P16473 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ CNR2 P34972 1/20 0.31
▸ MAPT P10636 2/20 0.30
▸ NPC1 O15118 1/20 0.30
▸ HTT P42858 1/20 0.30
▸ RAB9A P51151 1/20 0.30
▸ SMN1; SMN2 Q16637 1/20 0.30
▸ KDM4E B2RXH2 1/20 0.30
▸ MEN1 O00255 1/20 0.30
▸ MAPK1 P28482 1/20 0.30
▸ KMT2A Q03164 1/20 0.30
▸ HPRT1 P00492 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18233737 0.78 GPR84 (0.34) ALDH1A1CYP2A6TSHRHSD17B10TDP1
SCHEMBL26596973 0.76 EGFR (0.39) EGFRALDH1A1CYP2A6TSHRHSD17B10
SCHEMBL22792573 0.67 — —
SCHEMBL22792420 0.65 DRD1 (0.30) —
SCHEMBL22792595 0.65 BRD4 (0.33) —
SCHEMBL14584046 0.64 GPR3 (0.46) ALDH1A1TSHRTDP1MAPTSMN1; SMN2
SCHEMBL14584041 0.64 GPR3 (0.37) ALDH1A1TSHRTDP1HTTKDM4E
SCHEMBL21931156 0.63 MAPK1 (0.37) ALDH1A1CYP2A6TSHRHSD17B10TDP1
SCHEMBL122923 0.63 KDM4E (0.41) ALDH1A1CYP2A6TSHRHSD17B10TDP1
SCHEMBL23957953 0.62 BRD4 (0.37) TSHRHSD17B10TDP1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200392128-A1 NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2020-12-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200392128-A1 NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS PTPN5, PTPN1, PTPRJ EGFR 1014/4885ALDH1A1 2690/4885CYP2A6 3126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback